Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
June 18, 20214:23 AM PDTLast Updated a month ago
Healthcare & Pharmaceuticals
Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer’s drug
Julie SteenhuysenDeena Beasley

4 minute read
A sign marks a Biogen facility, some of whose employees have tested positive for the coronavirus after attending a meeting in Boston, in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder
June 18 (Reuters) - Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging next year could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc (BIIB.O) treatment without clear evidence that it works.
In approving Biogen’s Aduhelm over the objection of its own panel of outside expert advisers, the U.S. Food and Drug Administration has required a trial to confirm that the medicine will indeed slow progression of the lethal, mind-wasting disease - a process that could take several years - even as the drug is being used by patients.
But data expected much sooner on three drugs that work in a similar manner - Eli Lilly and Co's (LLY.N) donanemab, Roche Holding AG's (ROG.S) gantenerumab, and partners Eisai Co (4523.T) and Biogen's lecanemab - could give the medical community a better sense of whether Aduhelm is up to the job of slowing the ravages of Alzheimer's.
Aduhelm was approved last week based on its ability to clear a type of plaque from the brain that is believed to be a possible cause of Alzheimer’s, rather than evidence that it slows disease progression. The FDA contends the plaque removal is likely to benefit patients, an assertion many experts say is unproven.
"I don't feel that we have evidence now that there's a clinical benefit from reducing amyloid," said Dr. Henry Paulson, a neurologist who leads the University of Michigan's Alzheimer’s Disease Center.
"If another independent study of a different anti-amyloid therapy shows a clear clinical benefit, it makes me much more comfortable with continued use of Aduhelm," he said.
All four drugs are antibodies aimed at reducing the accumulation of the sticky plaques composed of a protein called beta amyloid found in the brains of people with Alzheimer's, a disease that currently afflicts some six million Americans.
Positive data from the three experimental medicines could also provide an indication of future competition for Aduhelm, which was developed in partnership with Eisai and is currently the only drug that targets an underlying cause of the disease.
Large clinical trials of Aduhelm, known chemically as aducanumab, produced contradictory data, with one trial failing and another showing benefit. There was also a potentially serious brain swelling side effect.
Nevertheless, the FDA approved Aduhelm under its "accelerated approval" program with the understanding that Biogen would conduct a post-marking study to demonstrate patient benefit.
FDA officials said other Alzheimer's drugs will not automatically be eligible for that program. "We can't say right now whether this will be a path for other Alzheimer's drugs, or drugs for other neurodegenerative diseases," Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, told Reuters.
Critics say the decision does change the landscape for future drugs.
"This is precedent-setting whether the FDA likes it or not," said Dr. Caleb Alexander, a Johns Hopkins public health professor and one of the remaining members of the FDA advisory panel that reviewed Aduhelm. Three members of the panel resigned after the FDA approval.
"That's not to suggest that the next drug that lowers amyloid is a slam dunk or even gets approved. It may not," he said.
For the near future, Biogen will have the market to itself, but analysts are watching potential future rivals closely.
"If another drug comes along and maybe doesn't have as many side effects, or maybe has slightly better data, Biogen's position could be jeopardized," said Raymond James health policy analyst Chris Meekins.
Japan's Eisai completed enrollment last month in a pivotal 18-month study of lecanemab in symptomatic early Alzheimer's patients. The drug is also being studied in a large trial of people with evidence of amyloid in their brains who do not yet have symptoms of the disease.
Roche, which has released limited gantenerumab trial findings, said it expects to have data next year from two global late-stage studies of its drug.
Eli Lilly announced encouraging results in March from a mid-stage study of donanemab and plans to conduct a larger trial.
“I think it is quite likely that if they can replicate those results it would be approved,” said Dr. David Knopman, a neurologist at the Mayo Clinic in Rochester, who quit FDA’s advisory panel in protest over the Aduhelm approval.
Reporting by Deena Beasley in Los Angeles and Julie Steenhuysen in Chicago; Editing by Peter Henderson and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page
Read Next
United States
New York City, California mandate COVID-19 vaccines for government workers
12:25 PM PDT
United Kingdom
UK expands daily COVID-19 testing to more key employers
12:18 PM PDT
Russia approves trials of combined AstraZeneca/Sputnik V vaccine
12:17 PM PDT
Healthcare & Pharmaceuticals
People with allergic reaction to mRNA vaccines can get 2nd dose; Delta viral load over 1,000 times higher
12:18 PM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 10:22 AM PDT
How the Delta variant upends assumptions about the coronavirus
The Delta variant is the fastest, fittest and most formidable version of the coronavirus that causes COVID-19 the world has encountered, and it is upending assumptions about the disease even as nations loosen restrictions and open their economies, according to virologists and epidemiologists.
Healthcare & Pharmaceuticals
Moderna in talks with FDA to expand COVID-19 vaccine pediatric study
11:20 AM PDT
Healthcare & Pharmaceuticals
Israel weighing COVID booster shots for over 60s before FDA approval
9:42 AM PDT
Healthcare & Pharmaceuticals
BioNTech aims to develop mRNA-based malaria vaccine
10:42 AM PDT
Healthcare & Pharmaceuticals
Biden pushes for long COVID sufferers to be protected by law
11:46 AM PDT
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved